<DOC>
	<DOCNO>NCT00622115</DOCNO>
	<brief_summary>Primary objective : - characterize pharmacokinetic pharmacodynamic profile intravenous bolus injection unfractionated heparin ( UFH ) repeat sc 100 IU anti-Xa/kg ( correspond 1 mg/kg ) twice day 2.5 day ( every 12±2hrs ) administration enoxaparin Caucasian healthy subject . Secondary objective ( ) : - compare pharmacokinetic pharmacodynamic profile 3 different time administration UFH - assess tolerability different anticoagulation protocol</brief_summary>
	<brief_title>Etude ( Study ) Phase I Enox - UnFractionated Heparin ( UFH )</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Caucasian Male female subject , 40 60 year age Body weight 50 kg 90 kg male 40 80 kg female Body Mass Index ( BMI ) 18 29 kg/m2 Health Status : Certified healthy comprehensive clinical assessment ( detailed medical history complete physical examination ) Subject hypertension , hypo hyperthyroidism dyslipidemia include concomitant pathology wellcontrolled treatment least one year Normal vital sign 10 minute rest supine position : 95 mmHg &lt; systolic blood pressure ( SBP ) &lt; 140 mmHg ; 45 mmHg &lt; diastolic blood pressure ( DBP ) &lt; 90 mmHg ; 40 bpm &lt; heart rate &lt; 100 bpm . Normal 12lead electrocardiogram ( ECG ) ; 120 m &lt; PR &lt; 220 m , QRS &lt; 120 m , QTc ≤ 430 m male , 450 m female consider clinically significant investigator Laboratory parameter within normal range unless Investigator considers abnormality clinically irrelevant healthy subject ; hepatic enzyme ( aspartate aminotransferase AST , alanine aminotransferase ALT ) strictly upper laboratory norm . Platelets ≥ 150 000 / mm3 Mean corpuscular volume ( MCV ) gamma glutamyltransferase ( GGT ) strictly normal range laboratory Activated partial thromboplastin time ( aPTT ) ratio comprise 0.95 1.15 Estimated Creatinine clearance Cockroft formula high 50 mL/min Non smoker smoke equivalent le 5 cigarette day able smoke study hospitalization Normal gynecological examination longer 12 month inclusion . For female childbearing potential use effective contraception method ( e.g . intrauterine device , hormonal contraception , diaphragm condom ) except postmenopausal 12 month sterilize three month Subject coagulation test blood count ( include platelet ) within physiological range ) Regulations : Having give write informed consent prior procedure relate study Covered Health Insurance System and/or compliance recommendation National Law force relate biomedical research Not administrative legal supervision Medical history clinical status : Contraindication anticoagulant therapy Subject know increase bleeding time , hemophilia , thrombocytopenia , and/or history vascular purpura Subject detectable antibody heparin blood Any history presence clinically relevant cardiovascular , gynecologic ( woman ) , pulmonary , gastrointestinal , hepatic , renal , metabolic , hematological , neurologic , psychiatric , systemic , ocular infectious disease capable alter absorption , metabolism , elimination drug , constitute risk factor take study medication ; acute infectious disease sign acute illness ; except subject hypertension , hypo hyperthyroidism dyslipidemia wellcontrolled treatment least one year . Subject diabetes cardiovascular metabolic disease Subject INR &gt; 1.5 Frequent headache and/or migraine , recurrent nausea and/or vomiting ( twice month ) Blood donation blood loss within one month administration Symptomatic hypotension whatever decrease blood pressure asymptomatic postural hypotension define decrease SBP equal great 20 mmHg within three minute change supine stand position Presence history drug allergy , allergic disease diagnose treated physician History presence drug alcohol abuse ( alcohol consumption &gt; 40 grams/day ) Smoking 5 cigarette equivalent/day , unable stop smoking study Excessive consumption beverage xanthine base ( &gt; 4 cup glasses/day ) Pregnancy ( define positive betaHCG plasma test explicate menopause ) , breastfeed female , history presence clinically relevant gynecologic disease Interfering substance : Any medication ( include St John 's Wort ) within 14 day administration , within 5 time elimination halflife drug , except hormonal contraception replacement therapy , allow therapy stable pathology Antiinflammatory treatment antiaggregant treatment strictly forbidden whole study period General condition : Subject , judgment Investigator , likely noncompliant study , unable cooperate language problem poor mental development Subject exclusion period previous study accord applicable regulation Subject contact case emergency Subject investigator subinvestigator , research assistant , pharmacist , study coordinator , staff thereof , directly involve conduct protocol protocol Investigating Center Subject employee Investigating Center Biological status : Positive reaction follow test : HBs antigen , antiHCV antibody , antiHIV1 antibody , antiHIV2 antibody , antiLMWH antibody Positive result urine drug screen ( amphetamines/metamphetamines , barbiturate , benzodiazepine , cannabinoids ) Positive alcohol breath plasma test</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>